📢 A new IMMUcan publication in Cell Reports Medicine sheds light on response to chemo-immunotherapy in advanced #TNBC and highlights the contribution of the EORTC-1553-SPECTA platform to translational cancer research.
Read more: spectaplatform.org/2026/09/30/i...
#IMMUcan #SPECTA
Read more: spectaplatform.org/2026/09/30/i...
#IMMUcan #SPECTA
September 30, 2026 at 2:56 PM
📢 A new IMMUcan publication in Cell Reports Medicine sheds light on response to chemo-immunotherapy in advanced #TNBC and highlights the contribution of the EORTC-1553-SPECTA platform to translational cancer research.
Read more: spectaplatform.org/2026/09/30/i...
#IMMUcan #SPECTA
Read more: spectaplatform.org/2026/09/30/i...
#IMMUcan #SPECTA
🔬 IMMUcan at #ESMOImmuno25
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
December 16, 2025 at 10:07 AM
🔬 IMMUcan at #ESMOImmuno25
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
🔬 IMMUcan at #ESMOImmuno25 | Poster Highlight II
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
December 18, 2025 at 10:57 AM
🔬 IMMUcan at #ESMOImmuno25 | Poster Highlight II
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
Multi-modal image analysis for large scale cancer tissue studies within IMMUcan https://www.biorxiv.org/content/10.1101/2024.12.16.628597v1
January 3, 2025 at 7:49 PM
Multi-modal image analysis for large scale cancer tissue studies within IMMUcan https://www.biorxiv.org/content/10.1101/2024.12.16.628597v1
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan
Eling and Dorier et al. present standardized workflows for multiplexed immunofluorescence and imaging mass cytometry, enabling large-scale profiling of thousands of cancer tissues in the pan-European IMMUcan consortium. The authors demonstrate high cross-technology consistency and release open-source tools and datasets to support community-wide immune landscape studies.
dlvr.it
September 9, 2025 at 10:59 PM
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan
Spatial transcriptomics = gene activity + location.
In IMMUcan, it shows where tumour & immune cells interact, and how that shapes treatment response. A living map of the tumour microenvironment.
In IMMUcan, it shows where tumour & immune cells interact, and how that shapes treatment response. A living map of the tumour microenvironment.
October 10, 2025 at 11:20 AM
Spatial transcriptomics = gene activity + location.
In IMMUcan, it shows where tumour & immune cells interact, and how that shapes treatment response. A living map of the tumour microenvironment.
In IMMUcan, it shows where tumour & immune cells interact, and how that shapes treatment response. A living map of the tumour microenvironment.
IMMUcan’s strength lies in its community — brilliant minds united to turn complex data into patient impact.
Huge thanks to all teams, coordinators & contributors driving this collaboration forward. 🙌
#IMMUcan #Collaboration #DataScience
Huge thanks to all teams, coordinators & contributors driving this collaboration forward. 🙌
#IMMUcan #Collaboration #DataScience
November 3, 2025 at 9:57 AM
IMMUcan’s strength lies in its community — brilliant minds united to turn complex data into patient impact.
Huge thanks to all teams, coordinators & contributors driving this collaboration forward. 🙌
#IMMUcan #Collaboration #DataScience
Huge thanks to all teams, coordinators & contributors driving this collaboration forward. 🙌
#IMMUcan #Collaboration #DataScience
How do cancers evade the immune system?
IMMUcan is helping decode the mechanisms (antigen presentation loss, immune suppression, dynamic resistance) through spatial & single-cell tech.
Understanding this is key to improving immunotherapy.
IMMUcan is helping decode the mechanisms (antigen presentation loss, immune suppression, dynamic resistance) through spatial & single-cell tech.
Understanding this is key to improving immunotherapy.
August 26, 2025 at 9:55 AM
How do cancers evade the immune system?
IMMUcan is helping decode the mechanisms (antigen presentation loss, immune suppression, dynamic resistance) through spatial & single-cell tech.
Understanding this is key to improving immunotherapy.
IMMUcan is helping decode the mechanisms (antigen presentation loss, immune suppression, dynamic resistance) through spatial & single-cell tech.
Understanding this is key to improving immunotherapy.
RRID:AB_467556 from @thermofishersci.bsky.social was used by authors in their paper. RRIDs improve reproducibility in scientific research. #OpenScience #accelerateopenscience #reproducibility
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan
doi.org
October 24, 2025 at 7:00 AM
RRID:AB_467556 from @thermofishersci.bsky.social was used by authors in their paper. RRIDs improve reproducibility in scientific research. #OpenScience #accelerateopenscience #reproducibility
What if we could decode what’s happening inside a tumour?
IMMUcan has profiled 2,600+ samples across cancer types using multi-omics tech.
We’re mapping how immune & #cancer cells interact, and what signals shape response or resistance.
We aim to predict what #treatment works for each patient.
IMMUcan has profiled 2,600+ samples across cancer types using multi-omics tech.
We’re mapping how immune & #cancer cells interact, and what signals shape response or resistance.
We aim to predict what #treatment works for each patient.
August 19, 2025 at 9:35 AM
What if we could decode what’s happening inside a tumour?
IMMUcan has profiled 2,600+ samples across cancer types using multi-omics tech.
We’re mapping how immune & #cancer cells interact, and what signals shape response or resistance.
We aim to predict what #treatment works for each patient.
IMMUcan has profiled 2,600+ samples across cancer types using multi-omics tech.
We’re mapping how immune & #cancer cells interact, and what signals shape response or resistance.
We aim to predict what #treatment works for each patient.
The authors included RRIDs in their in Clinical Cancer Research paper! RRIDs improve reproducibility in scientific research. #OpenScience #methodsmatter #OpenResearch
Molecular and immune landscape of recurrent and/or distant metastatic squamous cell carcinoma of the head and neck: an EORTC/IMMUCAN project
Read the full paper: Molecular and immune landscape of recurrent and/or distant metastatic squamous cell carcinoma of the head and neck: an EORTC/IMMUCAN project
doi.org
July 4, 2026 at 7:03 AM
The authors included RRIDs in their in Clinical Cancer Research paper! RRIDs improve reproducibility in scientific research. #OpenScience #methodsmatter #OpenResearch
Projects end, but their impact continues. As #IMMUcan concludes after 7 years, we reflect on key lessons: adaptability, strong collaboration, high-quality data from day one, and the importance of trust behind every dataset. Explore the project's legacy: www.immucan.eu
June 30, 2026 at 12:21 PM
Projects end, but their impact continues. As #IMMUcan concludes after 7 years, we reflect on key lessons: adaptability, strong collaboration, high-quality data from day one, and the importance of trust behind every dataset. Explore the project's legacy: www.immucan.eu
Thank you to all patients, researchers, clinicians and partners who made this journey possible.
Learn more about IMMUcan's research, datasets and scientific outputs: immucan.eu
Learn more about IMMUcan's research, datasets and scientific outputs: immucan.eu
IMMUcan - European immuno-oncology profiling platform
IMMUcan’s mission is to understand how the immune system and tumours interact and the impact of therapies
immucan.eu
June 19, 2026 at 10:00 AM
Thank you to all patients, researchers, clinicians and partners who made this journey possible.
Learn more about IMMUcan's research, datasets and scientific outputs: immucan.eu
Learn more about IMMUcan's research, datasets and scientific outputs: immucan.eu
After more than 7 years of collaboration, discovery and knowledge-sharing, IMMUcan leaves behind a significant scientific legacy.
June 19, 2026 at 10:00 AM
After more than 7 years of collaboration, discovery and knowledge-sharing, IMMUcan leaves behind a significant scientific legacy.
Good morning from Berlin! The final IMMUcan General Assembly starts today.
Over the years, IMMUcan has become one of Europe’s largest efforts to profile the tumour microenvironment across cancers, bringing together a wide community.
Time to take stock and look ahead!
#CancerResearch
Over the years, IMMUcan has become one of Europe’s largest efforts to profile the tumour microenvironment across cancers, bringing together a wide community.
Time to take stock and look ahead!
#CancerResearch
May 12, 2026 at 8:01 AM
Good morning from Berlin! The final IMMUcan General Assembly starts today.
Over the years, IMMUcan has become one of Europe’s largest efforts to profile the tumour microenvironment across cancers, bringing together a wide community.
Time to take stock and look ahead!
#CancerResearch
Over the years, IMMUcan has become one of Europe’s largest efforts to profile the tumour microenvironment across cancers, bringing together a wide community.
Time to take stock and look ahead!
#CancerResearch
Explore access: immucan.eu/how-to-colla...
IMMUcan - How to Collaborate?
IMMUcan proposes many opportunities for collaboration associated with benefits if you are clinician, study sponsor, patient or researcher
immucan.eu
March 9, 2026 at 9:56 AM
Explore access: immucan.eu/how-to-colla...
Read the paper:
www.cell.com/cell-reports...
www.cell.com/cell-reports...
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan
Eling and Dorier et al. present standardized workflows for multiplexed immunofluorescence
and imaging mass cytometry, enabling large-scale profiling of thousands of cancer
tissues in the pan-European ...
www.cell.com
March 9, 2026 at 9:56 AM
Read the paper:
www.cell.com/cell-reports...
www.cell.com/cell-reports...
MMUcan data are driving methods innovation.
A Cell Reports Methods study presents scalable multimodal imaging workflows built on IMMUcan tissue data.
A Cell Reports Methods study presents scalable multimodal imaging workflows built on IMMUcan tissue data.
March 9, 2026 at 9:55 AM
MMUcan data are driving methods innovation.
A Cell Reports Methods study presents scalable multimodal imaging workflows built on IMMUcan tissue data.
A Cell Reports Methods study presents scalable multimodal imaging workflows built on IMMUcan tissue data.
IMMUcan data contributed to a 2024 Immunity paper on CD4⁺ T cell activation and response to PD-L1/CTLA-4 blockade.
Collaborate: immucan.eu/how-to-colla...
Collaborate: immucan.eu/how-to-colla...
February 17, 2026 at 1:24 PM
IMMUcan data contributed to a 2024 Immunity paper on CD4⁺ T cell activation and response to PD-L1/CTLA-4 blockade.
Collaborate: immucan.eu/how-to-colla...
Collaborate: immucan.eu/how-to-colla...
High-impact cancer research starts with the right samples.
IMMUcan opens access to trial-grade oncology biosamples from ~1,400 patients.
immucan.eu/how-to-colla...
#CancerResearch #ImmunoOncology #Biomarkers #MultiOmics
IMMUcan opens access to trial-grade oncology biosamples from ~1,400 patients.
immucan.eu/how-to-colla...
#CancerResearch #ImmunoOncology #Biomarkers #MultiOmics
February 3, 2026 at 1:57 PM
High-impact cancer research starts with the right samples.
IMMUcan opens access to trial-grade oncology biosamples from ~1,400 patients.
immucan.eu/how-to-colla...
#CancerResearch #ImmunoOncology #Biomarkers #MultiOmics
IMMUcan opens access to trial-grade oncology biosamples from ~1,400 patients.
immucan.eu/how-to-colla...
#CancerResearch #ImmunoOncology #Biomarkers #MultiOmics
As 2025 comes to a close, we're grateful for the progress made through IMMUcan — advancing multi-omics data and deepening our understanding of the tumour microenvironment.
Thank you to all patients, clinicians, researchers & collaborators.
✨ Happy Holidays from the IMMUcan team! ✨
Thank you to all patients, clinicians, researchers & collaborators.
✨ Happy Holidays from the IMMUcan team! ✨
December 19, 2025 at 10:09 AM
As 2025 comes to a close, we're grateful for the progress made through IMMUcan — advancing multi-omics data and deepening our understanding of the tumour microenvironment.
Thank you to all patients, clinicians, researchers & collaborators.
✨ Happy Holidays from the IMMUcan team! ✨
Thank you to all patients, clinicians, researchers & collaborators.
✨ Happy Holidays from the IMMUcan team! ✨
New IMMUcan preprint on early-stage NSCLC just released.
A major multi-institutional effort. Congrats to all contributors! 👏
www.medrxiv.org/content/10.1...
A major multi-institutional effort. Congrats to all contributors! 👏
www.medrxiv.org/content/10.1...
December 3, 2025 at 10:52 AM
New IMMUcan preprint on early-stage NSCLC just released.
A major multi-institutional effort. Congrats to all contributors! 👏
www.medrxiv.org/content/10.1...
A major multi-institutional effort. Congrats to all contributors! 👏
www.medrxiv.org/content/10.1...
Excited to see the Cellohood preprint out — a big step forward for understanding tumor–immune interactions within IMMUcan.
A great milestone for a strong collaborative effort. Congrats to all co-authors! 👏
🔗 www.biorxiv.org/content/10.1...
A great milestone for a strong collaborative effort. Congrats to all co-authors! 👏
🔗 www.biorxiv.org/content/10.1...
November 20, 2025 at 10:22 AM
Excited to see the Cellohood preprint out — a big step forward for understanding tumor–immune interactions within IMMUcan.
A great milestone for a strong collaborative effort. Congrats to all co-authors! 👏
🔗 www.biorxiv.org/content/10.1...
A great milestone for a strong collaborative effort. Congrats to all co-authors! 👏
🔗 www.biorxiv.org/content/10.1...
Last week, the IMMUcan consortium met at EORTC Brussels (27–28 Oct 2025) for two days of inspiring discussions and data exploration. 💡
Researchers, clinicians & data scientists from across Europe shared results and shaped the next steps in cancer-immune research.
Researchers, clinicians & data scientists from across Europe shared results and shaped the next steps in cancer-immune research.
November 3, 2025 at 9:56 AM
Last week, the IMMUcan consortium met at EORTC Brussels (27–28 Oct 2025) for two days of inspiring discussions and data exploration. 💡
Researchers, clinicians & data scientists from across Europe shared results and shaped the next steps in cancer-immune research.
Researchers, clinicians & data scientists from across Europe shared results and shaped the next steps in cancer-immune research.
IMMUcan represents collaboration in action.
Clinicians & researchers across Europe are building one of the largest tumour–immune profiling efforts to date.
Together, we’re turning complexity into impact.
Learn more about our consortium: immucan.eu
Clinicians & researchers across Europe are building one of the largest tumour–immune profiling efforts to date.
Together, we’re turning complexity into impact.
Learn more about our consortium: immucan.eu
October 24, 2025 at 11:08 AM
IMMUcan represents collaboration in action.
Clinicians & researchers across Europe are building one of the largest tumour–immune profiling efforts to date.
Together, we’re turning complexity into impact.
Learn more about our consortium: immucan.eu
Clinicians & researchers across Europe are building one of the largest tumour–immune profiling efforts to date.
Together, we’re turning complexity into impact.
Learn more about our consortium: immucan.eu